185 related articles for article (PubMed ID: 14739683)
1. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy.
Hajioff D; Enever Y; Quiney R; Zuckerman J; Mackermot K; Mehta A
J Inherit Metab Dis; 2003; 26(8):787-94. PubMed ID: 14739683
[TBL] [Abstract][Full Text] [Related]
2. Hearing improvement in patients with Fabry disease treated with agalsidase alfa.
Hajioff D; Goodwin S; Quiney R; Zuckerman J; MacDermot KD; Mehta A
Acta Paediatr Suppl; 2003 Dec; 92(443):28-30; discussion 27. PubMed ID: 14989462
[TBL] [Abstract][Full Text] [Related]
3. Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey.
Hajioff D; Hegemann S; Conti G; Beck M; Sunder-Plassmann G; Widmer U; Mehta A; Keilmann A
Eur J Clin Invest; 2006 Sep; 36(9):663-7. PubMed ID: 16919050
[TBL] [Abstract][Full Text] [Related]
4. Hearing loss in Fabry disease: data from the Fabry Outcome Survey.
Hegemann S; Hajioff D; Conti G; Beck M; Sunder-Plassmann G; Widmer U; Mehta A; Keilmann A
Eur J Clin Invest; 2006 Sep; 36(9):654-62. PubMed ID: 16919049
[TBL] [Abstract][Full Text] [Related]
5. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
6. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
Kampmann C; Linhart A; Devereux RB; Schiffmann R
Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
[TBL] [Abstract][Full Text] [Related]
7. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
[TBL] [Abstract][Full Text] [Related]
9. Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy.
Sergi B; Conti G; Paludetti G;
Acta Otorhinolaryngol Ital; 2010 Apr; 30(2):87-93. PubMed ID: 20559478
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
11. Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females.
Conti G; Sergi B
Acta Paediatr Suppl; 2003 Dec; 92(443):33-7; discussion 27. PubMed ID: 14989464
[TBL] [Abstract][Full Text] [Related]
12. Agalsidase alfa: specific treatment for Fabry disease.
Mehta A
Hosp Med; 2002 Jun; 63(6):347-50. PubMed ID: 12096664
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
Ries M; Clarke JT; Whybra C; Timmons M; Robinson C; Schlaggar BL; Pastores G; Lien YH; Kampmann C; Brady RO; Beck M; Schiffmann R
Pediatrics; 2006 Sep; 118(3):924-32. PubMed ID: 16950982
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy of Fabry disease.
Clarke JT; Iwanochko RM
Mol Neurobiol; 2005 Aug; 32(1):43-50. PubMed ID: 16077182
[TBL] [Abstract][Full Text] [Related]
15. Update on role of agalsidase alfa in management of Fabry disease.
Ramaswami U
Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
[TBL] [Abstract][Full Text] [Related]
16. Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease.
Dehout F; Roland D; Treille de Granseigne S; Guillaume B; Van Maldergem L
J Inherit Metab Dis; 2004; 27(4):499-505. PubMed ID: 15303007
[TBL] [Abstract][Full Text] [Related]
17. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
18. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
[TBL] [Abstract][Full Text] [Related]
19. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.
Banikazemi M; Bultas J; Waldek S; Wilcox WR; Whitley CB; McDonald M; Finkel R; Packman S; Bichet DG; Warnock DG; Desnick RJ;
Ann Intern Med; 2007 Jan; 146(2):77-86. PubMed ID: 17179052
[TBL] [Abstract][Full Text] [Related]
20. Treatment with agalsidase beta during pregnancy in Fabry disease.
Politei JM
J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]